Stockscreener 앱 받기
34.84
0.78%
0.27
시장 영업 전:
35.02
0.18
+0.52%
Exelixis Inc 주식(EXEL)의 최신 뉴스
The Smartest Biotech Stocks to Buy With $50 - The Motley Fool
FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs - MarketBeat
Is Exelixis, Inc. (EXEL) The Most Profitable Biotech Stock To Buy Right Now? - Insider Monkey
Trexquant Investment LP Has $19.82 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Blair William & Co. IL Sells 300,760 Shares of Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
New Age Alpha Advisors LLC Makes New $2.10 Million Investment in Exelixis, Inc. (NASDAQ:EXEL) - MarketBeat
Exelixis Launches Special Equity Award Program - TipRanks
(EXEL) Long Term Investment Analysis - news.stocktradersdaily.com
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors - MSN
What is Leerink Partnrs' Estimate for Exelixis Q1 Earnings? - MarketBeat
Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment - MSN
Exelixis stock holds $40 target post FDA nod By Investing.com - Investing.com South Africa
FDA Expands Exelixis Cabometyx Label For Neuroendocrine Tumors - Barchart.com
Exelixis’ cabozantinib approval ‘certainly positive,’ says Citi - Yahoo Finance
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL) - The Globe and Mail
Exelixis stock holds $40 target post FDA nod - Investing.com
Stifel maintains Exelixis stock hold, $36 target post FDA nod By Investing.com - Investing.com South Africa
FDA approves new treatment for advanced neuroendocrine tumors By Investing.com - Investing.com South Africa
Exelixis to present positive preclinical data across pipeline portfolio at AACR - Yahoo Finance
Leerink lifts Exelixis stock target to $33 post FDA approval By Investing.com - Investing.com Australia
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold? - TradingView
Leerink lifts Exelixis stock target to $33 post FDA approval - Investing.com India
Stifel maintains Exelixis stock hold, $36 target post FDA nod - Investing.com India
Exelixis’ primary cancer drug wins FDA approval for neuroendocrine tumors - Endpoints News
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors - Benzinga
Exelixis (NasdaqGS:EXEL) Celebrates FDA Approval For Expanded CABOMETYX® Use In Treating NET - Yahoo Finance
Citi maintains Buy on Exelixis stock with $45 target By Investing.com - Investing.com Canada
Citi maintains Buy on Exelixis stock with $45 target - Investing.com India
Exelixis' cancer drug gets FDA approval but analysts say its priced in; shares down - TradingView
Exelixis wins FDA label expansion for Cabometyx (EXEL:NASDAQ) - Seeking Alpha
Exelixis Gets FDA Approval for Drug Treating Patients With Previously Treated Advanced Neuroendocrine Tumors - MarketScreener
Exelixis Gets Expanded FDA Approval of Cabometyx in Advanced Neuroendocrine Tumors - MarketWatch
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis Announces U.S. FDA Approval Of CABOMETYX® (cabozantinib) For Patients With Previously Treated Advanced Neuroendocrine Tumors - MarketScreener
FDA approves new treatment for advanced neuroendocrine tumors - Investing.com
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Joplin Globe
(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
FDA Approves Cabozantinib For Adults And Pediatric Patients 12 Years Of Age And Older With pNET And epNET - MarketScreener
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025 - BioSpace
Looking Into Exelixis's Recent Short Interest - Benzinga
Exelixis (NASDAQ:EXEL) shareholders have earned a 16% CAGR over the last five years - simplywall.st
Biotech Leader Exelixis Eyes Buy Point In Today's Stock Market Rally - MSN
Interesting EXEL Put And Call Options For November 21st - Nasdaq
Learn to Evaluate (EXEL) using the Charts - Stock Traders Daily
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Exelixis Growth Continues with Big Money Boosts - Yahoo Finance
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA - Business Wire
Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
0.48%
자본화:
|
볼륨(24시간):